Learn about career opportunities with Southern Research »
BIRMINGHAM, Ala. and EXTON, Penn. (January 30, 2007) - Executives with Southern Research Institute and Absorption Systems, LP today announced that they have signed an agreement that will allow the two organizations to collaborate in providing contract research services in the areas of toxicology and bioanalytical services to biotechnology and pharmaceutical clients.
According to the agreement, Southern Research and Absorption Systems will work jointly to offer expanded preclinical development services to their clients for new compounds about to enter clinical development, and will conduct collaborative business development, co-marketing and scientific publication projects. Financial terms of the agreement were not announced.
"We are very pleased to be working with Southern Research. This collaboration will allow us to combine Southern Research's world-renowned toxicology services and drug development expertise with Absorption System's expertise in bioanalytical services, metabolite profiling, and preclinical formulation development in order provide the highest quality services to the pharmaceutical and biotech industry," said Patrick Dentinger, president and CEO of Absorption Systems.
"The relationship with Absorption Systems will allow both companies to leverage our individual strengths for the benefit of our pharmaceutical and biotech clients by generating better and faster study data as new drugs move forward," said Tina S. Rogers, Ph.D., vice president of the Drug Development Division at Southern Research.
About Absorption Systems, LP
Founded in 1996, Absorption Systems, LP (ASLP) focuses on performing assays that can predict the Absorption, Distribution, Metabolism, and Excretion (ADME) of small molecules using a variety of in vitro, in situ, and in vivo models. ASLP supports these assays with state-of-the-art bioanalytical capabilities and preclinical formulation services. For more information, visit www.absorption.com.
About Southern Research Institute
Southern Research Institute is a not-for-profit organization that conducts basic and applied research in the areas of preclinical drug discovery and development. To date, Southern Research has discovered a record six cancer drugs that have received FDA-approval, with another six compounds currently in late-stage preclinical development or clinical trials. Southern Research has evaluated nearly 70 percent of all other FDA-approved cancer drugs and 75 percent of all FDA-approved HIV drugs currently on the market. For more information, please visit www.SouthernResearch.org.